https://www.selleckchem.com/pr....oducts/cct241533-hyd
Although the safety and feasibility of rapid rituximab administration has been demonstrated for B-cell malignancies, there is scant data in the literature to support its use in patients with benign diseases. To identify the incidence of infusion-related reaction with rapid rituximab administration in malignant and benign disease. Secondary objective was to determine the infusion time saved between standard administration and rapid rituximab administration. A retrospective cohort study was conducted by reviewing electroni
Like
Comment
Share
